Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
By R. Stupp, W. Mason, M. V. D. Bent, Michael Weller, Barbara Fisher, M. Taphoorn, Karl Bélanger, A. Brandes, Christine Marosi, Ulrich Bogdahn and 9 more. New England Journal of Medicine, 2005
20,077 citations recorded by the source corpus.
BACKGROUND Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy. In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety. METHODS Patients with newly diagnosed, histologically confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle). The primary end point was overall survival. RESULTS A total of 573 patients from 85 centers underwent randomization. The median age was 56 years, and 84 percent of patients had undergone debulking surgery. At a median follow-up of 28 months, the median survival was 14.6 months with radiotherapy plus temozolomide and 12.1 months with radiotherapy alone. The unadjusted hazard ratio for death in the radiotherapy-plus-temozolomide group was 0.63 (95 percent confidence interval, 0.52 to 0.75; P<0.001 by the log-rank test). The two-year survival rate was 26.5 percent with radiotherapy plus temozolomide and 10.4 percent with radiotherapy alone. Concomitant treatment with radiotherapy plus temozolomide resulted in grade 3 or 4 hematologic toxic effects in 7 percent of patients. CONCLUSIONS The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
Subfields: Genetics
View Paper: https://www.semanticscholar.org/paper/e4b17209bfffb5809810c87fbb2079cb9263f7d0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
- M. Davis
- Jeremy N. Rich
- Eric C. Holland
- J. Joyce
- D. Quail
- Michael Weller
- J. Lathia
- Anita B. Hjelmeland
Citations in the corpus
- EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME: IDENTIFICATION OF AND ADJUSTMENT FOR BIAS (2008, methodology): “, European Organisation for Research and Treatment of Cancer Study 26981) (13), did not incorporate early postoperative MRI as part of the study protocol.”
- Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. (2014, background): “New England Journal of Medicine, 370(8): 709-722 http://dx.”
- Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers (2008, background): “Glioblastomas are highly malignant brain tumours with a poor prognosis, despite intensive research and clinical effort”
- Long-term survival with glioblastoma multiforme. (2007, background): “Chemotherapy for malignant gliomas has experienced a renaissance since the publication of the EORTC 26981/22981-NCIC CE3 phase III randomized trial, which demonstrated that concomitant and adjuvant temozolomide chemotherapy has a positive effect on survival of patients with glioblastoma (Stupp et al”
- Integrin alpha 6 regulates glioblastoma stem cells (2010, background): “Gliobastoma multiforme (GBM) is the most common and lethal primary brain tumor with less than 3% 5 year survival rate (Stupp et al., 2005).”
- Cost of disorders of the brain in Europe 2010. (2011, neutral): “While the treatment of meningioma has not consistently changed in recent years, the state of the art therapy in high grade glioma is currently surgery followed by radiotherapy with concomitant and adjuvant temozolomide (Stupp et al., 2005).”